NIR-PIT can convert a minimally immunogenic tumor into a highly immunogenic tumor by increasing the number and density of activated CD8+ T cells in tumor beds leading to improved efficacy with anti-PD-1 ICI. The gene discussed is PDCD1; the disease is neoplasm.